Clear Street analyst Bill Maughan downgraded CRISPR Therapeutics (NASDAQ: CRSP) from Buy to Hold.The analyst comments "We are downgrading shares ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE